Retrieve available abstracts of 10 articles: HTML format
Single Articles
May 2025
TU ZL, Tu JF Cholelithiasis, Cholecystitis, and Choledocholithiasis.
N Engl J Med. 2025;392:e42. PubMed
May 2024
KOWDLEY KV, Levy C, Jones D Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
Reply.
N Engl J Med. 2024;390:1935-1936. PubMed
HIRSCHFIELD GM, Kremer AE, Levy C Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
Reply.
N Engl J Med. 2024;390:1934-1935. PubMed
IJICHI H Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
N Engl J Med. 2024;390:1934. PubMed
AREVALO-CANAS C, Arevalo-Serrano J Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
N Engl J Med. 2024;390:1933-1934. PubMed
February 2024
SCHNABL B PPAR Agonists in Primary Biliary Cholangitis.
N Engl J Med. 2024;390:855-858. PubMed
HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med. 2024;390:783-794. PubMedAbstract available
ASSIS DN Advancing Second-Line Treatment for Primary Biliary Cholangitis.
N Engl J Med. 2024;390:853-854. PubMed
November 2023
KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185. PubMedAbstract available
August 2023
CHAVES JJ, Chaves-Chamorro JO Biliary Ascariasis.
N Engl J Med. 2023;389:839. PubMed